Phys Vivas · general-medicine
Rheumatological Examination Spine AND Lower Limbs — Viva Defence
DCE viva defence for Rheumatological Examination Spine AND Lower Limbs.
On this page
Study tools
Target exams
Rheumatological Examination Spine AND Lower Limbs Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Rheumatological Examination Spine AND Lower Limbs. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up."
Examiner questions
Q1: "What makes this urgent?"
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up."
Q2: "What is your first investigation package?"
"I order tests that change management now, not a scattergun panel."
Q3: "Walk me through treatment."
"Stabilise, treat the mechanism, prevent complications, and plan monitoring."
Q4: "What is the classic trap?"
"Treating a label without confirming the discriminating mechanism, or delaying escalation."
References5ShowHide
- [1]Kalish RA, Wohlgethan JR, Liu N, et al. Promoting the utilization of rheumatologic musculoskeletal anatomy: a 50-year travel log Clin Rheumatol, 2026.PMID 42334785
- [2]Perrot S, Laroche F, Poncet C, et al. Are joint and soft tissue injections painful? Results of a national French cross-sectional study of procedural pain in rheumatological practice BMC Musculoskelet Disord, 2010.PMID 20100351
- [3]Venyte R, Schuster-Amft C, Behrendt F, et al. [Long-standing myalgia and hypouricemia in a young woman : Case report and review of the literature] Z Rheumatol, 2025.PMID 40810925
- [4]Sukharomana M, Charuvanij S Implementation and assessment of a structured curriculum for a 4-week pediatric rheumatology rotation for pediatric residents BMC Med Educ, 2024.PMID 38263148
- [5]Yamamuro K, Ide K, Arai Y, et al. Association Between Participant Satisfaction and Self-Reported Clinical Practice Behaviors in a Nationwide Guideline Education Program Neuropsychopharmacol Rep, 2026.PMID 42448624